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non-alcoholic fatty liver disease in Hispanic
adolescents in NHANES 2003–2010
Sofia G. Verstraete, Janet M. Wojcicki* , Emily R. Perito and Philip Rosenthal
Abstract
Background: Bisphenol-A (BPA) is a ubiquitous chemical and recognized endocrine disruptor associated with
obesity and related disorders. We explored the association between BPA levels and suspected non-alcoholic fatty
liver disease (NAFLD).
Methods: Unweighted analyses were used to study the relationship between urinary BPA levels and suspected
NAFLD (alanine aminotransferase (ALT).
> 30 U/L, body mass index (BMI) Z-score > 1.064 and evidence of insulin resistance) using National Health and
Nutrition Examination Survey (NHANES) data (2003–2010) on 12–19 year olds. Unweighted and weighted analyses
were used to evaluate the risk with only elevated ALT.
Results: We included 944 adolescents with urinary BPA and fasting laboratory tests from a total of 7168 adolescents.
Risk of suspected NAFLD was increased in the second quartile of BPA levels (1.4–2.7 ng/mL) when compared to the
first (< 1.4 ng/mL) (Odds Ratio (OR) 4.23, 95% Confidence Interval (CI) 1.44–12.41). The ORs for the third and second
quartiles were positive but did not reach statistical significance. The association was stronger in Hispanics (n = 344) with
BPA levels in the second (OR 6.12, 95% C.I. 1.62–23.15) quartile and when limiting the analyses to overweight/obese
adolescents (n= 332), in the second (OR 5.56, 95% C.I. 1.28–24.06) and fourth BPA quartiles (OR 6.85, 95% C.I. 1.02–46.22)
compared to the first quartile. BPA levels were not associated with ALT elevation.
Conclusions: The risk of suspected NAFLD is increased in participants in higher quartiles of BPA exposure, particularly in
those of Hispanic ethnicity. Further studies are required to fully understand the potential role of BPA in non-alcoholic fatty
liver disease.
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Background
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver disease in children and
adolescents in the United States [1–4] with up to 38% of
obese children affected [5]. Prevalence increases with age,
reaching approximately 17.5% in adolescents [5], and with
5 times the risk of fatty liver in Hispanics [5–7]. Although
it is a histologic diagnosis, NAFLD is clinically suspected
when steatosis is identified in imaging studies or with
elevation of transaminases in otherwise healthy children,
particularly in overweight children or those with evidence
of insulin resistance [8]. While genetics clearly play some
role in NAFLD [9, 10], environmental exposures may also
be inciting or exacerbating factors [11, 12].
Bisphenol-A (BPA) is a ubiquitous chemical and likely
endocrine disruptor [13]. It was first synthesized in the
1940s as a synthetic estrogen and is now used in thermal
receipt paper as well as coatings that prevent metal cor-
rosion of food and beverage containers [14]. In vitro and
animal studies have shown that BPA contributes to de
novo fatty acid synthesis [15], stimulates the accumula-
tion of triacylglycerol in adipocytes and human hepato-
cellular carcinoma cells [16] and up- regulates gene
expression involved in lipid metabolism and insulin
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resistance (IR) [17, 18]—all mechanisms that may con-
tribute to NAFLD. In humans, obesity and diabetes have
been associated with serum and urine concentrations of
some environmental chemicals, leading to the hypothesis
that these chemicals interfere with aspects of metabol-
ism [19–21]. In adults, exposure to BPA is associated
with obesity, type 2 diabetes mellitus (DM), cardiovascu-
lar disease, and increased serum gamma glutamyl trans-
peptidase and alkaline phosphatase levels [22, 23]. Dose
responsive associations have been reported between
urinary BPA and fasting blood glucose and metabolites
of oxidative stress [24, 25], which also contribute to the
development of NAFLD. Although previous cross-sectional
studies have found that urinary BPA concentration was sig-
nificantly associated with obesity in children and adoles-
cents [26–28], the association between elevated BPA and
NAFLD has not been studied.
The aim of this study is to specifically explore the rela-
tionship between BPA exposure in US adolescents and
suspected NAFLD defined as elevated ALT levels, over-
weight or obesity and evidence of insulin resistance.
Secondary aims include stratification of the above relation-
ship according to race/ethnicity given the high prevalence
of NAFLD in Hispanic adolescents, and assessing the rela-
tionship between BPA exposure in US adolescents and
ALT elevation.
Methods
Study design
The National Health and Nutrition Examination Survey
(NHANES) [29] is a nationally representative survey of
the civilian non-institutionalized U.S. population carried
out by the National Center for Health Statistics (NCHS)
of the Centers for Disease Control and Prevention
(CDC). Survey cycles from 2003–2004 to 2009–2010
were used to obtain the questionnaire, laboratory, diet
and physical examination components for our analysis.
Previous cycles that did not include urinary BPA levels
and posterior cycles where fasting laboratory levels had
not been published at the time of the analysis were ex-
cluded. NHANES is approved by the NCHS Research
Ethics Review Board, and written informed consent and
child assent (as appropriate) were obtained from partici-
pants. The Institutional Review Board at the University
of California, San Francisco (Committee for Human
Research) exempted the present study from review.
Inclusion criteria
Adolescent participants between the ages of 12 and 19
were selected for inclusion in this study. Urinary BPA
levels were available for a random third and fasting labora-
tory results were available for a separate random half of
participants (both randomly selected by NHANES [30]).
Only those included in both random subsets were
included in our overall analysis. Participants who were
pregnant or known to have Hepatitis B or C, Human
Immunodeficiency Virus (HIV), known liver disease, or
known exposure to hepatotoxic medication (see Supple-
mentary Table 1) were excluded from the analysis. The in-
clusion process is detailed in Fig. 1.
Method for BPA concentration assessment
A randomly selected subsample had total urinary BPA
concentration measured in a urine sample for each par-
ticipant [31, 32]. Concentrations were obtained using
high performance liquid chromatography and tandem
mass spectroscopy [30]. A value of 0.28 ng/mL was
substituted when urinary BPA concentrations were
below the level of detection, as is routinely assigned by
the NHANES [33]. One hundred patients (3.5%) had
urinary concentrations below this level. Urinary cre-
atinine was included in all multivariate models to cor-
rect for urinary dilution, as done in previous
publications [34, 35]. Our primary predictor was BPA
level categorized into quartiles. Log-transformed total
concentrations of BPA levels were also estimated and
used independently as a predictor in the analyses.
Definition of suspected non-alcoholic fatty liver disease
(NAFLD)
Our primary study outcome was the presence or absence
of suspected NAFLD. Participants were determined to
have suspected NAFLD if they had elevated alanine
transaminase (ALT) (ALT ≥30 U/L) in combination with
overweight [BMI z score of 1.036 or greater (85th per-
centile for age and sex)] or obesity [BMI z- score
1.064 or greater (95th percentile for age and sex)] and
evidence of insulin resistance [Homeostatic Model
Assessment for Insulin Resistance (HOMA-IR) ≥3.16].
HOMA-IR was calculated by dividing the product of
fasting insulin (mU/L) times fasting plasma glucose
(mmol/L) by 22.5 [36]. BMI z-scores were derived
using the norms suggested by the Centers for Disease
Control and Prevention [37]. Secondary analyses were
conducted using elevated ALT (ALT ≥30 U/L) [38] as
an outcome. Sensitivity analyses were conducted using
a higher cutoff for ALT (> 50 U/L in boys, > 44 U/L in
girls) as a more specific marker for identifying obese
children at high risk for NAFLD [39].
Definition and inclusion of potential confounders
Potential confounders were identified in the current
literature [26–28, 40]. Statistical modeling was used to
determine causal relationships. Variables that were
identified as possible confounders and were available in
NHANES included age, gender, race/ethnicity, country
of birth, poverty to income ratio, survey cycle year ex-
posure to tobacco using serum cotinine as a surrogate,
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and total caloric intake in 24 h. Race/ethnicity were
categorized based on self-report by caregivers in
participants under 16 years of age, and by participants
in those over 17 years of age. Given that exposure to
tobacco smoke is a risk factor for metabolic syndrome
in adolescence, serum cotinine level was included in all
multivariate models as a continuous variable. A variable
characterizing survey cycle year was included in all
multivariable models since median urinary BPA levels
were not uniform across survey cycles. Urinary BPA in
the 2003–2004 cycle had a median of 4.3 ng/mL (IQR
2–7.5), while levels for the 2005–2006, 2007–2008, and
2009–2010 cycles were 2.4 ng/mL, 2 ng/mL, and
2.1 ng/mL respectively.
Statistical analysis
Multivariate logistic regression models were conducted
using Stata 12.0 (Stata Corp, College Station TX) follow-
ing NCHS recommendations. Following the practice of
Trasande [41] and Stahlhut [42], unweighted analyses
were used as our primary analytic approach since the
studied population consisted of two overlapping NHANES
subsamples. Although there are subsample weights for
each, combining these would decrease the sample size ul-
timately resulting in unstable and unreliable statistical
estimates. Additional sensitivity analyses were performed.
For the secondary analysis of ALT elevation, we per-
formed both an unweighted analysis for comparison with
our primary outcome, and a weighted analysis following
the NCHS guidelines to adjust for the complex survey
structure of NHANES. All multivariate models were ad-
justed for urinary creatinine concentrations to account for
dilution of urinary BPA.
Results
In the four NHANES cycles studied (2003–2010), 7168
adolescents between the ages of 12 and 19 were evalu-
ated. Urinary BPA concentrations were obtained in 2238
(31.2%). Fasting laboratory values needed to compute
HOMA-IR (insulin and glucose) were available in a
second randomized subsample of 976 participants
(43.6%). Thirty-two participants (3.3%) were excluded
due to pregnancy (n = 21), exposure to hepatotoxic med-
ications (n = 9), or evidence of hepatitis B or C (n = 2).
None had HIV or other known liver disease. Our pri-
mary, unweighted analysis thus included 944 adolescents
from 12 to 19 years of age with both fasting bloodwork
and urinary BPA concentrations. The population se-
lected is illustrated in Fig. 1.
Fig. 1 Population Included in Analysis
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For the analysis of ALT elevation, 2105 participants
had available BPA concentrations and ALT. Of these,
1978 participants were included in secondary weighted
and unweighted analyses after exclusions for pregnancy
(n = 38), hepatitis B or C (n = 5), and exposure to hep-
atotoxic medications (n = 30).
Descriptive and bivariate analyses of urinary BPA quar-
tiles and demographic, environmental, and dietary data
for those included in the study (n = 944) are presented in
Table 1. Median urinary BPA in the suspected NAFLD
cohort was 2.6 ng/mL (interquartile range, IQR, 1.3–
5.3 ng/mL). ALT was elevated in 8.4% n = 80), and sus-
pected NAFLD, as defined above, was present in 4.8%
(n = 44) (Table 1). For the secondary analysis (n = 1978)
including the larger sample of those with ALT and BPA
concentrations only, median urinary BPA was 4.73 (IQR
0.28–149) and ALT was elevated in 9.81% (n = 194)
(results not shown).
For the smaller cohort with fasting labs and weights,
BPA concentrations in Hispanic participants were lowest
(median BPA 2.1 ng/mL, IQR 1–3.8), with slightly higher
concentrations in non-Hispanic white participants (median
BPA 2.8 ng/mL, IQR 1.4–6) and significantly higher con-
centrations in non-Hispanic black participants (median
BPA 3.6 ng/mL, IQR 1.7–6.5) (results not shown). This dif-
ference in BPA concentrations among race/ethnicity cate-
gories is also reflected in the distribution of race/ethnicity
among quartiles of urinary BPA (p < 0.001; see Table 1).
Table 1 Demographic data by Bisphenol-A Quartile for NHANES Populationg
n (%) Bisphenol-A quartile
0.28–1.3 ng/mL 1.4–2.7 ng/mL 2.8–5.4 ng/mL ≥5.5 ng/mL p-value
n = 944 n = 250 (%) n = 240 (%) n = 225 (%) n = 228
Age (years)f 15.5 ± 2.3 15.1 ± 2.2 15.5 ± 2.3 15.6 ± 2.3 15.6 ± 2.4 0.03
Gender (male) 523 (55.4) 141 (56.4) 134 (55.8) 118 (52.4) 130 (56.8) 0.78
Country of Birth
United States 822 (87.1) 213 (85.2) 207 (86.3) 204 (90.7) 198 (86.5)
Mexico 69 (7.3) 19 (7.6) 21 (8.8) 13 (5.8) 16 (7.0) 0.51
Other 53 (5.6) 18 (7.2) 12 (5.0) 8 (3.6) 15 (6.6)
Poverty to Income Ratiof 2.07 + 1.51 2.11 ± 1.48 2.10 ± 1.49 2.00 ± 1.51 2.08 ± 1.56 0.87
Race/Ethnicity
Non-Hispanic White 256 (27.1) 61 (24.4) 66 (27.5) 58 (25.8) 71 (31)
Hispanic 344 (36.4) 117 (46.8) 98 (40.8) 74 (32.9) 55 (24) < 0.001
Non-Hispanic Black 297 (31.5) 54 (21.6) 67 (27.9) 82 (36.4) 94 (41.1)
Other 47 (5.0) 18 (7.2) 9 (3.8) 11 (4.9) 9 (3.9)
Tobacco Exposure (by cotininelevel)
Low (< 0.015 ng/mLa) 168 (18.0) 59 (23.7) 52 (21.8) 38 (17.1) 19 (8.4)
Medium (0.015 to < 2 ng/mL) 603 (64.4) 159 (63.9) 150 (62.8) 140 (63.1) 154 (68.1) < 0.001
High (≥2 ng/mL) 165 (17.6) 31 (12.5) 37 (15.5) 44 (19.8) 53 (23.5)
Daily Caloric Intake (kilocalories)f 2270.9 ± 1030.3 2319.8 ± 1090.3 2347.8 ± 1069.8 2209.1 ± 940.0 2199.6 ± 1005.9 0.30
BMI Z-Score ≥ 1.036 (≥85th Percentile) 332 (35.6) 80 (32.3) 87 (36.9) 79 (3.3) 86 (38.4) 0.54
Metabolic Syndrome 101 (10.8) 29 (11.7) 23 (9.7) 22 (9.9) 27 (12.0) 0.80
Hypertriglyceridemiab 97 (10.3) 23 (9.2) 23 (9.6) 23 (10.3) 28 (12.3) 0.70
Low High Density Lipoproteinc 249 (26.6) 71 (28.5) 51 (21.3) 64 (28.8) 63 (28.0) 0.20
Hypertensiond 260 (27.6) 62 (24.8) 61 (25.4) 62 (27.6) 75 (32.8) 0.20
Waist Circumference > 90th 201 (21.8) 51 (20.6) 51 (21.9) 48 (21.8) 51 (23.1) 0.93
Percentile
Impaired fasting glucose 189 (20) 59 (23.6) 57 (23.8) 36 (16.0) 37 (16.2) 0.04
Alanine Aminotransferase > 30 U/Le 80 (8.58) 18 (7.23) 29 (12.18) 14 (6.33) 19 (8.48) 0.11
Suspected Non-Alcoholic Fatty Liver Disease 44 (4.8) 7 (2.83) 17 (7.3) 9 (4.1) 11 (5.1) 0.14
aTo convert cotinine to nmol/L multiply by 5.675, bSerum triglycerides ≥150 mg/dL (for conversion to mmol/L multiply by 0.0113), cHDL < 40 mg/dL (for
conversion to mmol/L multiply by 0.259), dSystolic and/or diastolic blood pressure > 85th percentile for age/height, eTo convert to ukat/L multiply by 0.0167,
fMean ± SD, gNHANES population limited to those with fasting lab draws and body mass index measurements in addition to BPA
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Urinary BPA and non-alcoholic Steatohepatitis
In logistic regression models adjusting only for urinary
creatinine, there were no no associations between sus-
pected NAFLD and increasing BPA concentrations
(Table 2). In multivariate models adjusting for all con-
founders, the odds of suspected NAFLD were increased
in the second quartile of urinary BPA concentration
[Odds Ratio (OR) 4.23, 95% Confidence Interval (CI)
1.44–12.41] (Table 2). The association was not observed
in the third and fourth quartiles of BPA concentrations.]
Suspected NAFLD was present in 24 (7.04%) Hispanic,
12 (4.88%) non-Hispanic white, 6 (2.09%) non-Hispanic
black, and 2 (4.55%) other race participants out of the
44 total (result not shown). Multivariate analysis in non-
Hispanic White and Hispanic populations showed that
Hispanic participants with urinary BPA in the second
quartile of BPA concentrations were at higher risk for
suspected NAFLD than those in the lowest quartile of
BPA (Table 2). Suspected NAFLD was too rare in non-
Hispanic black and other categories to evaluate the role
of BPA quartile on suspected NAFLD in stratified
analyses.
The analyses were repeated including only overweight
and obese participants (Table 3). There was a stronger
association between suspected NAFLD and the second
quartile of BPA concentrations (OR 5.56, 95% C.I. 1.28–
24.06) (Table 3). When limiting the analysis to over-
weight and obese Hispanic participants, there was an
even higher risk of suspected NAFLD in the second BPA
quartile (OR 5.00, 1.40–17.93; p = 0.015) (Table 3).
Urinary BPA and elevated ALT
In our secondary analysis of weighted analyses elevated
ALT alone, there were no significant associations with
urinary BPA in the second (OR 1.34, 95% C.I. 0.57–
3.11), third (OR 1.13, 95% C.I. 0.69–2.66), or fourth (OR
1.35, 95% C.I. 0.57–3.20) quartiles when compared to
the first quartile in multivariate models. Additionally, no
associations were found in univariate models, when
evaluating BPA as a log-transformed continuous vari-
able, after stratification for race/ethnicty or in any un-
weighted analyses using our standard cut-off limit for
ALT (> 30 U/L) or after sensitivity analyses using higher
cutoffs (data not shown).
Discussion
This is the first study to evaluate the association be-
tween BPA and suspected NAFLD. In a relatively large
and well-characterized sample of US adolescents we
found that the odds of suspected NAFLD were higher in
the second quartile of BPA concentrations. Additionally,
this association was higher in Hispanic adolescents.
These associations persisted after limiting analyses to
only the Hispanic population. ALT elevation was not as-
sociated with BPA concentration.
We hypothesize that we had an improved ability to
detect an association in Hispanic adolescents because
the prevalence of NAFLD in Hispanic participants
(7%) was higher than in non-Hispanic whites (4.8%),
non-Hispanic blacks (2.1%) or other participants
(4.6%) in our population. We suspect that low preva-
lence of elevated ALT and suspected NAFLD in the
cohort may have made it harder to detect an associ-
ation in the higher BPA quartiles. Furthermore, wide
confidence intervals in these quartiles suggest that a
small sample size hindered detection of an association
between urinary BPA and suspected NAFLD in the
upper BPA quartiles. Alternatively, a non-monotonic
dose-response relationship, where the risk of disease is
highest with low, constant doses, may exist with ex-
posure to BPA. In animal studies, metabolic dysfunc-
tion has been identified with exposure to “low doses”
(doses generally considered safe for human exposure)
of BPA [25].
Table 2 Risk of Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Risk of Suspected NAFLDa in total population
All races (n = 944) Non-hispanic white (n = 256) Hispanic (n = 344)
Unadjusted modeld Adjusted modele Adjusted modelf Adjusted modelf
OR (95% C.I.)c p-value OR (95% C.I.) p-value OR (95% C.I.) p-value OR (95% C.I.) p-value
Urinary BPAb Category
0.28–1.3 ng/mL Reference Reference Reference Reference
1.4–2.7 ng/mL 2.66 (0.94–7.48) 0.064 4.23 (1.44–12.41) 0.010 1.69 (0.26–10.92) 0.571 6.12 (1.62–23.15) 0.009
2.8–5.4 ng/mL 1.95 (0.57–6.71) 0.281 2.43 (0.57–10.43) 0.225 1.19 (0.09–15.63) 0.887 2.74 (0.42–17.70) 0.281
≥5.5 ng/mL 2.12 (0.58–7.72) 0.248 3.39 (0.78–14.80) 0.101 1.30 (0.06–27.62) 0.862 4.21 (0.74–24.11) 0.104
Log Transformed BPA
1.07 (0.69–1.67) 0.757 1.20 (0.75–1.91) 0.444 1.22 (0.48–3.12) 0.674 1.02 (0.61–1.72) 0.937
aNon-Alcoholic Fatty Liver Disease, bBisphenol A, cOdds Ratio (95% Confidence Interval), dAdjusted for urinary creatinine, eAdjusted for urinary creatinine, gender,
age, race, family income to poverty ratio, country of birth, total caloric intake in 24 h, cotinine levels, and survey cycle, fAdjusted for urinary creatinine, gender,
age, total caloric intake in 24 h, cotinine levels, and survey cycle
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One prior publication explored the relationship between
BPA and elevated serum transaminases in boys. In a small
group (n = 39) of overweight and obese 3 to 8 year olds,
elevated serum aspartate aminotransferase (AST) was as-
sociated with increasing BPA concentrations [43] in male
participants. In a population based adult study, serum
gamma-glutamyl transpeptidase elevation was also associ-
ated with elevated BPA concentrations [22]. Neither of
these studies excluded other causes of liver disease.
We focused our definition of suspected NAFLD with
the aim of increasing the specificity of the diagnosis by
excluding other causes of elevated ALT concentrations.
The association between BPA and suspected NAFLD was
positive in using the more specific definition including
obesity and insulin resistance, but consistently negative
when using elevated ALT alone as an outcome, which
strengthens our hypothesis that BPA is associated with
NAFLD.
Obesity has been associated with BPA in previous
studies [26–28, 44], independent of any liver disease,
which raised the concern that the association with sus-
pected NAFLD may be due to using BMI ≥85th percent-
ile as part of the definition for suspected NAFLD.
Limiting the analysis to overweight or obese participants
allowed us to assess the strength of the association be-
tween BPA and NAFLD independent of weight categor-
ies. We found stronger associations between BPA and
NAFLD among the overweight and obese than among
the total cohort of 944. This suggests that BPA may be
contributing to the development of NAFLD, particularly
in Hispanics who are overweight/obese. Further studies
should investigate a possible interaction between BPA
consumption and higher weight categories and possible
development of NAFLD.
This study’s limitations are similar to those of other
studies of BPA and obesity or related outcomes. The
bulk of the literature studying these associations consists
of cross-sectional data [26–28, 40, 43–45], with the lar-
gest studied groups coming from NHANES [26, 28, 43].
All of the studies evaluating these associations use urin-
ary concentrations of BPA to determine exposure. Urin-
ary BPA concentrations are obtained from a single
sample, which is thought to reflect recent (4-40 h) diet-
ary intake and does not necessarily reflect chronically
high (or low) concentrations [32, 46] or long term ex-
posure. Moreover, studies have shown high variability
within individuals [47], as well as detectable concentra-
tions after fasting [48, 49], which suggest urinary BPA
concentrations may also reflect non-dietary exposure
or accumulation in tissue. Specifically, studies have
shown that BPA has a strong affinity for adipose tissue
with accumulation three times higher than in other tis-
sues [49]. BPA is ubiquitous in the environment but it
is difficult to evaluate long-term exposure with current
techniques.
BPA and NAFLD both inhibit human hepatic meta-
bolic activities [50, 51]. Additionally, BPA is subject to
hepatic metabolism where it is converted to an inactive
monoglucuronide form [50]. This is another important
limitation to our study- BPA metabolism may be im-
paired in NAFLD due to defective hepatic glucuronida-
tion increasing total BPA levels in urine. Studies in
animal models, patients affected by liver disease of other
etiologies and longitudinal studies in humans etiologies
are necessary to clarify this conundrum.
The relationship between BPA and NAFLD identified in
this large, nationally representative sample of adolescents
should encourage further research on the effect of BPA
and obesity related outcomes, particularly adequately sized
longitudinal studies to study causality. Further longitu-
dinal studies would help elucidate whether BPA concen-
trations are a risk factor for NAFLD or are increased in
obese children because they have greater adipose stores of
this lipophilic chemical. The association we found with
Table 3 Risk of Suspected Non-Alcoholic Fatty Liver Disease (NAFLD) in Overweight/Obese Adolescents
Risk of Suspected NAFLDa in overweight/obese participants (BMIb Z-Score ≥ 1.064)
All races (n = 327) Non-hispanic white (n=) Hispanic (n = 126)
Unadjusted modeld Adjusted modele Adjusted modelf Adjusted modelf
OR (95% C.I.)c p-value OR (95% C.I.) p-value OR (95% C.I.) p-value OR (95% C.I.) p-value
Urinary BPAg Category
0.28–1.3 ng/mL Reference Reference Reference
1.4–2.7 ng/mL 2.86 (0.98–8.29) 0.053 5.56 (1.28–24.06) 0.023 1.29 (0.12–13.89) 0.829 5.00 (1.40–17.93) 0.015
2.8–5.4 ng/mL 2.20 (0.61–7.93) 0.224 3.39 (0.60–19.13) 0.162 1.42 (0.04–45.42) 0.841 1.98 (0.23–17.43) 0.527
≥5.5 ng/mL 2.31 (0.66–8.01) 0.181 6.85 (1.02–46.22) 0.048 0.87 (0.05–16.55) 0.926 5.20 (0.93–29.01) 0.060
Log Transformed BPA
1.11 (0.71–1.73) 0.644 1.41 (0.74–2.70) 0.285 1.28 (0.19–8.59) 0.787 1.04 (0.58–1.85) 0.896
aNon-Alcoholic Fatty Liver Disease, bBody Mass Index, cOdds Ratio (95% Confidence Interval), dAdjusted for urinary creatinine, eAdjusted for urinary creatinine,
gender, age, race, family income to poverty ratio, country of birth, total caloric intake in 24 h, cotinine levels, and survey cycle, fAdjusted for urinary creatinine,
gender, age, total caloric intake in 24 h, cotinine levels, and survey cycle, gBisphenol A
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NAFLD suggests that BPA concentrations may be tied to
end-organ disease, not just co-existent with obesity.
Conclusion
In adolescents, particularly those of Hispanic ethnicity,
there is an association between Bisphenol-A and sus-
pected non-alcoholic fatty liver disease. Given the cross-
sectional nature of this study, we are unable to establish
true causality. Hispanics may be more prone to eating
poor quality foodstuff with additional environmental
toxins in addition to BPA which may have a cumulative
impact on risk for NAFLD. Our study further indicated
that there may important interactive effects between
overweight, obesity and ingestion of BPA and develop-
ment of NAFLD. It is possible that BPA accumulates in
adipose tissues as other studies have indicated. Further
longitudinal studies evaluating long-term exposure to
BPA, are needed to fully understand the role of BPA and
other environmental toxins in NAFLD, as well as pos-
sible mechanisms of injury.
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